For example, contrary to the positive results of the SINDAS trial that examined the effect of MDT consolidation in the setting of EGFR-mutated NSCLC, the NRG-BR002 trial, which tested the effect of local consolidation in oligometastatic breast cancer patients, found no significant difference in PFS or OS [23]. The gene discussed is EGFR; the disease is breast cancer.